Countdown to Zoetis (ZTS) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS

Wall Street analysts project Zoetis (ZTS) to report Q2 EPS of $1.61, a 3.2% year-over-year increase, and revenues of $2.4 billion, up 1.7%. The consensus EPS estimate has seen a 0.3% upward revision over the past 30 days, signaling positive analyst sentiment. While overall revenue growth is modest, segment estimates reveal a significant projected decline in Livestock revenue by 9.9% and a sharp 93.2% drop in Medicated Feed Additives, largely offset by robust 6.7% growth in Companion Animal revenue, particularly in international markets. This mixed outlook comes as ZTS shares have underperformed the S&P 500 over the last month.

Analysis

Zoetis (ZTS) is approaching its Q2 earnings with analyst expectations set for modest top-line growth but a more complex underlying performance. Consensus estimates project revenue to increase 1.7% year-over-year to $2.4 billion, with earnings per share rising 3.2% to $1.61. A key positive indicator is the 0.3% upward revision in the consensus EPS estimate over the past 30 days, a factor often associated with positive short-term price action post-announcement. However, a detailed look at segment forecasts reveals a significant divergence. The Companion Animal division is expected to be the primary growth engine, with revenues projected to climb 6.7% to $1.76 billion, led by strong international demand (+8.7%). This strength is critical as it is set against a substantial forecasted decline of 9.9% in the Livestock segment, which is experiencing a particularly sharp contraction of 11.3% in the U.S. market. While the dramatic 93.2% projected drop in Medicated Feed Additives is notable, its small revenue base mitigates the overall impact. This mixed fundamental outlook is mirrored in the stock's recent performance, which has fallen 6.5% in the past month, starkly underperforming the S&P 500's 2.7% gain, suggesting investors are weighing the slowing overall growth and livestock weakness against the positive EPS trend.

Key Decisions for Investors

• Focus on the upcoming earnings report, paying close attention to whether the robust 6.7% growth in the Companion Animal segment materializes to offset the steep 9.9% forecasted decline in Livestock revenue.
• Investors should carefully evaluate management's outlook and commentary regarding the U.S. Livestock business, as the projected 11.3% contraction in this area is a significant headwind that could dictate future performance.
• Considering the stock's recent underperformance against the market, a hold strategy may be prudent ahead of the report; a beat on the upwardly revised EPS of $1.61 could offer a near-term lift, but the divergent segment performance introduces considerable risk.